NEW YORK, April 7, 2017 /PRNewswire/ --
On Thursday, benchmark US indices were in bullish colors as the NASDAQ Compositeclosed the trading session up 0.25%; the Dow Jones Industrial Average edged 0.07% higher; and the S&P 500 was up 0.19%. US markets made broad based gains with six out of nine sectors finishing the day in green. Pre-market today, Stock-Callers.com
On Thursday, shares in Flint, Michigan headquartered Diplomat Pharmacy Inc. recorded a trading volume of 621,753 shares. The stock ended the day 0.77% higher at $14.38. The Company's shares are trading at a PE ratio of 34.57. Diplomat Pharmacy's stock has gained 9.19% in the past three months. The Company's shares are trading below its 50-day and 200-day moving averages by 2.68% and 36.53%, respectively. Furthermore, shares of Diplomat Pharmacy, which operates as an independent specialty pharmacy in the US, have a Relative Strength Index (RSI) of 40.53. Free research report on DPLO is available at:
Cambridge, Massachusetts headquartered Momenta Pharmaceuticals Inc.'s stock finished Thursday's session 1.50% higher at $13.55 with a total volume of 730,001 shares traded. Momenta Pharma's shares have gained 39.40% in the past one year. The Company's shares are trading above its 200-day moving average by 1.13%. Shares of Momenta Pharma, which focuses on developing generic versions of complex drugs, biosimilars, and novel therapeutics for autoimmune diseases in the US, have an RSI of 37.90. The complimentary research report on MNTA can be downloaded at:
Princeton, New Jersey headquartered Agile Therapeutics Inc.'s stock advanced 2.36%, to close the day at $3.04. The stock recorded a trading volume of 166,220 shares. Agile Therapeutics' shares have surged 41.40% in the last one month and 20.63% in the previous three months. The Company's shares are trading 21.56% above its 50-day moving average. Additionally, shares of the Company, which focuses on the development and commercialization of prescription contraceptive products for women, have an RSI of 57.25. Visit us today and access our complete research report on AGRX at:
On Thursday, shares in La Jolla, California-based Sophiris Bio Inc. ended the session 2.68% lower at $2.54 with a total volume of 402,637 shares traded. Sophiris Bio's shares have gained 2.83% in the last one month and 64.40% in the previous one year. The stock is trading 5.96% below its 50-day moving average and 17.03% below its 200-day moving average. Moreover, shares of the Company, which focuses on the development of products for the treatment of urological diseases, have an RSI of 42.42.
On March 13th, 2017, research firm Rodman & Renshaw initiated a 'Buy' rating on the Company's stock, with a target price of $6 per share. Get free access to your research report on SPHS at: http://stock-callers.com/registration/?symbol=SPHS
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: email@example.com Phone number: +44-330-808-3765 Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA
Subscribe to our Free Newsletters!